We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Stock Moves -0.95%: What You Should Know
Read MoreHide Full Article
In the latest trading session, McKesson (MCK - Free Report) closed at $312.03, marking a -0.95% move from the previous day. This change was narrower than the S&P 500's 2.38% loss on the day. Meanwhile, the Dow lost 1.94%, and the Nasdaq, a tech-heavy index, lost 0.6%.
Prior to today's trading, shares of the prescription drug distributor had lost 5.14% over the past month. This has lagged the Medical sector's gain of 1.41% and the S&P 500's loss of 0.07% in that time.
Wall Street will be looking for positivity from McKesson as it approaches its next earnings report date. In that report, analysts expect McKesson to post earnings of $5.29 per share. This would mark a year-over-year decline of 4.86%. Our most recent consensus estimate is calling for quarterly revenue of $63.62 billion, up 1.51% from the year-ago period.
MCK's full-year Zacks Consensus Estimates are calling for earnings of $23.25 per share and revenue of $264.78 billion. These results would represent year-over-year changes of -1.86% and +0.31%, respectively.
Investors should also note any recent changes to analyst estimates for McKesson. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.25% higher. McKesson is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that McKesson has a Forward P/E ratio of 13.55 right now. This valuation marks a discount compared to its industry's average Forward P/E of 19.96.
Investors should also note that MCK has a PEG ratio of 1.44 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Dental Supplies stocks are, on average, holding a PEG ratio of 2.33 based on yesterday's closing prices.
The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 241, which puts it in the bottom 5% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Stock Moves -0.95%: What You Should Know
In the latest trading session, McKesson (MCK - Free Report) closed at $312.03, marking a -0.95% move from the previous day. This change was narrower than the S&P 500's 2.38% loss on the day. Meanwhile, the Dow lost 1.94%, and the Nasdaq, a tech-heavy index, lost 0.6%.
Prior to today's trading, shares of the prescription drug distributor had lost 5.14% over the past month. This has lagged the Medical sector's gain of 1.41% and the S&P 500's loss of 0.07% in that time.
Wall Street will be looking for positivity from McKesson as it approaches its next earnings report date. In that report, analysts expect McKesson to post earnings of $5.29 per share. This would mark a year-over-year decline of 4.86%. Our most recent consensus estimate is calling for quarterly revenue of $63.62 billion, up 1.51% from the year-ago period.
MCK's full-year Zacks Consensus Estimates are calling for earnings of $23.25 per share and revenue of $264.78 billion. These results would represent year-over-year changes of -1.86% and +0.31%, respectively.
Investors should also note any recent changes to analyst estimates for McKesson. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.25% higher. McKesson is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that McKesson has a Forward P/E ratio of 13.55 right now. This valuation marks a discount compared to its industry's average Forward P/E of 19.96.
Investors should also note that MCK has a PEG ratio of 1.44 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Dental Supplies stocks are, on average, holding a PEG ratio of 2.33 based on yesterday's closing prices.
The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 241, which puts it in the bottom 5% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.